Alzamend Neuro (ALZN) Interest Coverage Ratio Growth (3y) (2023 - 2026)
Powered by 
Analysis
Alzamend Neuro (ALZN) Interest Coverage Ratio Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.94 Bn | 195.95 Bn | 7.24 Bn | 13.52% |
| 2 | Gilead Sciences | 179.74 Bn | 176.57 Bn | 6.22 Bn | -98.43% |
| 3 | Vertex Pharmaceuticals | 132.05 Bn | 124.20 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.43 Bn | 74.44 Bn | 3.93 Bn | 29.79% |
| 5 | Argenx Se | 61.23 Bn | 56.04 Bn | 1.37 Bn | 44.22% |
| 6 | Moderna | 53.42 Bn | 48.28 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.77 Bn | 30.47 Bn | 992.69 Mn | 33.30% |
| 8 | Biogen | 31.62 Bn | 30.33 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - | -44.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -44.31% |
| Jan 31, 2026 | 14.50% |
| Oct 31, 2025 | 24.22% |
| Jul 31, 2025 | 18.13% |
| Apr 30, 2025 | 29.67% |
| Jan 31, 2025 | -48.52% |
| Oct 31, 2024 | -20.14% |
| Jul 31, 2024 | 22.05% |
| Apr 30, 2024 | -153.47% |
| Jan 31, 2024 | -280.23% |
| Oct 31, 2023 | -197.29% |
| Jul 31, 2023 | 39.62% |